title: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.
abstract: OBJECTIVE
  Colon cancer is one of the major health problems in industrialized countries, and its incidence appears to be increasing. Surgical resectability is the most important prognostic determinant, although despite apparently curative surgery, recurrent tumors are common. Metastatic disease cannot be cured, and thus, there is a need for better adjuvant therapies.
  
  
  METHODS
  Two hundred and thirty-nine patients with surgically resected colon cancer in Dukes' stage B2 or C were randomly assigned to chemotherapy or observation alone to determine whether adjuvant chemotherapy could effectively reduce the rate of cancer recurrence. One hundred and twenty-one patients in stage B2 and 118 patients in stage C were enrolled in the study. Adjuvant treatment consisted of folinic acid 200 mg/m2, intravenously, plus 5-fluorouracil 400 mg/m2, intravenously, on days 1-5 every 4 weeks for 12 cycles.
  
  
  RESULTS
  In stage B2, no significant difference between the adjuvant arm and the observation arm was noted. In stage C, adjuvant chemotherapy produced an advantage over observation in terms of a reduction in cancer recurrence rate with prolongation of a disease-free interval (P = 0.0016) and an improvement in overall survival (P = 0.0025).
  
  
  CONCLUSIONS
  This study shows that folinic acid plus 5-fluorouracil adjuvant chemotherapy is effective in patients with surgically resected Dukes' stage C colon carcinoma.
authors.affiliation: Institute of Medical Pathology, S. Maria della Scala Hospital, University of Siena, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Francini
authors.forename: R
authors.initials: R
authors.lastname: Petrioli
authors.forename: L
authors.initials: L
authors.lastname: Lorenzini
authors.forename: S
authors.initials: S
authors.lastname: Mancini
authors.forename: S
authors.initials: S
authors.lastname: Armenio
authors.forename: G
authors.initials: G
authors.lastname: Tanzini
authors.forename: S
authors.initials: S
authors.lastname: Marsili
authors.forename: A
authors.initials: A
authors.lastname: Aquino
authors.forename: G
authors.initials: G
authors.lastname: Marzocca
authors.forename: S
authors.initials: S
authors.lastname: Civitelli
mesh_terms: D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016019:Survival Analysis
chemical_list: D002955:Leucovorin; D005472:Fluorouracil